On January 10, 2024, before market hours, Fuzzy Panda Research published a report alleging, among other things, that DocGo has been committing “systematic billing fraud” by forging signatures on documents, editing patient records to maximize profits, and billing for covid tests that were not performed.
On this news, DocGo’s stock price fell $1.80, or 37.6%, to close at $2.99 per share on January 10, 2024, thereby injuring investors.
Submit Your Information
If you suffered a loss on your DocGo Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.